CBD Reversed Autism-Related Behavioral Problems in a Mouse Model

In mice prenatally exposed to valproic acid (a model of autism), acute CBD at 30-60 mg/kg reversed pre-pulse inhibition deficits, decreased repetitive marble-burying, improved social interaction time, and restored object recognition memory. CBD at 60 mg/kg was effective across most tests but did not reduce stereotyped-like movements.

Animal study using the valproic acid (VPA) autism model in mice. Adult mice (8 weeks old) exposed to VPA prenatally received acute CBD (30 or 60 mg/kg) and were tested across five behavioral paradigms: pre-pulse inhibition, marble burying, social interaction, activity, and novel object recognition.

Autism spectrum disorder has limited treatment options, and many families report using CBD for their children. This preclinical study provides mechanistic support for CBD's potential to address multiple domains of autism-related behavior, particularly social deficits and cognitive impairment.

This animal study complements the emerging clinical trial data on CBD for autism. The finding that CBD addresses multiple behavioral domains but not all (stereotyped movements were unaffected) suggests that CBD may be useful for some aspects of autism while other symptoms may require different interventions.

Animal model using synthetic autism induction (VPA) may not capture the full complexity of human autism. Only acute, single-dose administration tested. Male mice only. Cannot determine long-term efficacy or safety. Doses used are high relative to typical human clinical doses.